The BRAF inhibitor vemurafenib was the first approved targeted therapy for BRAFV600E metastatic melanoma, achieving a response rate of 50% to 60% and significantly improving progression-free survival (PFS) and overall survival (OS) [4, 5]. The gene discussed is BRAF; the disease is metastatic melanoma.